Similar personal injury attorneys in New York
Prior results do not guarantee a similar outcome. Each case is unique and depends on its own facts.
About Ellen Relkin
Ellen Relkin is a partner and practice-group chair in the Drugs and Medical Devices unit at Weitz & Luxenberg. She has spent more than three decades representing people injured by dangerous pharmaceutical products, medical devices, and toxic chemicals, arguing that manufacturers routinely prioritize profits over safety by inadequately testing products, failing to warn consumers, and delaying corrective action. She clerked for Hon. Sylvia Pressler, then Presiding Judge of the New Jersey Superior Court Appellate Division, from 1984 to 1985. Relkin is a former chair of the American Association for Justice's Section on Toxic, Environmental, and Pharmaceutical Torts, an elected member of the American Law Institute, and a Fellow of the American Civil Justice Institute.
She received the New Jersey Association for Justice Gerald B. O'Connor Award for Professionalism in 2018. Her J.D. is from Rutgers University Law School (1984) and her B.A., cum laude in history with distinction, is from Cornell University (1980). She is admitted in New York, New Jersey, Pennsylvania, the District of Columbia, numerous federal district and circuit courts, and the U.S. Supreme Court.
Proven verdicts and settlements
Ellen Relkin served as court-appointed co-lead plaintiffs counsel in the DePuy ASR hip implant MDL, helping negotiate a $2.5 billion settlement for roughly 8,000 patients who required revision surgery after the metal-on-metal device failed.
Hours before opening arguments in the first federal opioid bellwether trial, Cuyahoga and Summit counties in Ohio secured a $260 million settlement from distributors AmerisourceBergen, Cardinal Health, and McKesson, plus manufacturer Teva.
San Francisco Unified School District's case was the first JUUL bellwether trial against Altria; after the plaintiffs rested, Altria agreed to pay $235 million to resolve roughly 6,000 pending e-vapor claims nationwide.
In early 2014, Biomet agreed to pay at least $56 million to settle about 1,000 federal lawsuits over its M2a 38 and M2a Magnum metal-on-metal hip implants, consolidated in the Northern District of Indiana. Qualifying patients who had the device revised received a base award of $200,000, adjusted by individual factors. Thomas Anapol was court-appointed Co-Lead Counsel with W. Mark Lanier and signed the agreement for the Plaintiffs' Executive Committee. The figure covers many unrelated plaintiffs, is a reported minimum rather than a final total, and is not itemized by person.
Prior results do not guarantee a similar outcome. Each case is unique and depends on its own facts.
Practice areas
Education
Bar admissions & credentials
Other attorneys at Weitz & Luxenberg
View firm →
Proven verdicts and settlements from other New York firms
Prior results do not guarantee a similar outcome. Each case is unique and depends on its own facts.